S
Stablix Therapeutics
Stablix | Protein Stabilization Therapeutics
About Stablix Therapeutics
Stablix is a groundbreaking startup operating in the pharmaceutical industry, specifically in the field of targeted deubiquitination therapeutics (TDT). In simpler terms, they are developing innovative medicines that target and modify specific proteins in the body to treat various diseases. Their work is aimed at patients who have unmet medical needs, particularly those suffering from rare diseases, cancer, and immunological disorders.
The company's business model revolves around the development and commercialization of their proprietary RESTORED™ platform. This platform generates unique molecules, called RESTORACs™, that can precisely remove ubiquitin, a protein that regulates the life cycle and activity of other proteins in the body. By targeting proteins that are subject to abnormal degradation, Stablix aims to restore deficient proteins to therapeutic levels, potentially providing a new treatment avenue for a variety of devastating diseases.
Stablix's approach to drug development is unique in that it leverages the body's own cellular machinery to combat disease. This innovative approach could potentially disrupt the pharmaceutical industry and establish a new paradigm for treating diverse diseases.
The company generates revenue through the development and eventual commercialization of their therapeutic drugs. As they progress through the stages of drug development, they may also seek partnerships with larger pharmaceutical companies for further development and distribution of their products.
In summary, Stablix is a pioneering pharmaceutical startup that leverages innovative technology to develop transformative medicines for patients with unmet medical needs. Their unique approach to drug development could potentially revolutionize the treatment of various diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 64.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2022 | $15M | $60M | Undisclosed | — |
| SERIES AOther financing | Jun 2021 | $63M | $252M | NEA · Alexandria Venture Investments · Cormorant Capital · Versant Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Stablix Therapeutics is 2.5K monthly website visits, up 31.6% over the last three months. Stablix Therapeutics's team declined 10.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Versant Ventures
NEA
Alexandria Venture Investments- CCCormorant Capital
- ECEuclidean Capital
Other known investors1 additional known investor
Columbia University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stablix Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stablix Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.